RMEBX | TQCIX | RMEBX / TQCIX | |
Total Expense Ratio | 1.07 | 0.65 | 165% |
Annual Report Gross Expense Ratio | 1.07 | 1.12 | 96% |
Fund Existence | 11 years | 4 years | - |
Gain YTD | 5.923 | 4.121 | 144% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 500000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 106B | 2.29B | 4,635% |
Annual Yield % from dividends | 1.16 | 1.90 | 61% |
Returns for 1 year | 8.54 | 5.23 | 163% |
Returns for 3 years | 27.89 | 24.39 | 114% |
Returns for 5 years | 58.69 | N/A | - |
Returns for 10 years | 68.22 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FBTIX | 29.15 | -0.19 | -0.65% |
Fidelity Advisor Biotechnology I | |||
MCGCX | 19.20 | -0.23 | -1.18% |
BlackRock Advantage Global Investor C | |||
RTNAX | 12.98 | -0.17 | -1.29% |
Russell Inv Tax-Managed Intl Eq A | |||
RYYCX | 153.09 | -2.43 | -1.56% |
Rydex S&P SmallCap 600 Pure Value C | |||
ARIBX | 14.51 | -0.25 | -1.69% |
Aristotle Small Cap Eq I |